Erlotinib, Bevacizumab, and Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Colorectal Cancer - Related Studies

Erlotinib, Bevacizumab, and Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Colorectal Cancer

This study has been completed.

Study NCT00060411. Last updated on July 23, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Colorectal Cancer

2	Additional conditions recognized in this trial
		Colorectal Neoplasms

3	More general conditions related to this trial
		Colonic Diseases
		Digestive System Diseases
		Digestive System Neoplasms
		Gastrointestinal Diseases
		Gastrointestinal Neoplasms
		Intestinal Diseases
		Intestinal Neoplasms
		Neoplasms
		Neoplasms by Site
		Rectal Diseases

4	Interventions listed in this trial
		bevacizumab
		erlotinib hydrochloride
		fluorouracil
		leucovorin calcium
		oxaliplatin

5	Additional drug interventions recognized in this trial
		Erlotinib
		Leucovorin

6	More general drug interventions related to this trial
		Angiogenesis Inhibitors
		Angiogenesis Modulating Agents
		Antimetabolites
		Antimetabolites, Antineoplastic
		Antineoplastic Agents
		Enzyme Inhibitors
		Growth Inhibitors
		Growth Substances
		Immunologic Factors
		Immunosuppressive Agents
		Micronutrients
		Molecular Mechanisms of Pharmacological Action
		Pharmacologic Actions
		Physiological Effects of Drugs
		Protein Kinase Inhibitors
		Therapeutic Uses
		Vitamin B Complex
		Vitamins

7	Sponsors listed in this trial
		Sidney Kimmel Comprehensive Cancer Center
		National Cancer Institute (NCI)